OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Immunology Immunotherapy is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML c	132
Host B cells escape CAR-T immunotherapy by reversible downregulation of CD19	122
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma	119
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study	119
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma	100
A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model	61
Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells	58
A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes	55
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter ret	53
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers	52
Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies	52
Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer	52
Cytokine alterations during paraneoplastic neutrophilia and leukemoid reaction in patients with advanced melanoma	43
Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and m	42
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition	40
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study	40
Bis-indole-derived NR4A1 antagonists inhibit colon tumor and splenic growth and T-cell exhaustion	39
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist	39
Reovirus combined with a STING agonist enhances anti-tumor immunity in a mouse model of colorectal cancer	38
Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma	38
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas	37
Costimulatory molecule expression profile as a biomarker to predict prognosis and chemotherapy response for patients with small cell lung cancer	37
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors	37
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents	35
Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens	35

Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate	35
GK-1 effectively reduces angiogenesis and prevents T cell exhaustion in a breast cancer murine experimental model	34
A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs	34
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors	33
Combination therapy with dendritic cell loaded-exosomes supplemented with PD-1 inhibition at different time points have superior antitumor effect in hepatocellular carcinoma	33
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma	32
Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy	32
Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells	32
Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)	31
Radiation-associated secondary malignancies: a novel opportunity for applying immunotherapies	31
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial	31
Correction to: Myeloid-derived suppressor cells cross-talk with B10 cells by BAFF/BAFF-R pathway to promote immunosuppression in cervical cancer	31
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy	30
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study	30
Pharmacological potentiation of monocyte-derived dendritic cell cancer immunotherapy	30
Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy	30
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free	29
Identification of the molecular subtype and prognostic characteristics of pancreatic cancer based on CD8 + T cell-related genes	29
Cancer immunity and immunotherapy beyond COVID-19	29
Personalized tumor vaccine for pancreatic cancer	29
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial	28
Rescue of NLRC5 expression restores antigen processing machinery in head and neck cancer cells lacking functional STAT1 and p53	28
Comprehensive analysis of the immunological implication and prognostic value of CXCR4 in non-small cell lung cancer	28
LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells	27
Single-cell analysis of peripheral CD8+ T cell responses in patients receiving checkpoint blockade immunotherapy for cancer	27
Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics	27
A Fc-VEGF chimeric fusion enhances PD-L1 immunotherapy via inducing immune reprogramming and infiltration in the immunosuppressive tumor microenvironment	26
PD-1 Inhibitors combined with paclitaxel (Albumin-bound) and cisplatin for larynx preservation in locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: a retrospective study	25
Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function	25
Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis	25
The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer	25
Peptide vaccine from cancer-testis antigen ODF2 can potentiate the cytotoxic T lymphocyte infiltration through IL-15 in non-MSI-H colorectal cancer	25
Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors	24
Radiation-induced dormancy of intracerebral melanoma: endotoxin inflammation leads to both shortened tumor dormancy and long-term survival with localized senescence	24
Organ-on-a-chip models for development of cancer immunotherapies	24
Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia	24
Live attenuated VZV vaccination induces antitumor immunity in ATLL patients	24
Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia	24
Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma	24
TCR extracellular domain genetically linked to CD28, 2B4/41BB and DAP10/CD3ζ -engineered NK cells mediates antitumor effects	24
Pretreatment blast-to-lymphocyte ratio as a prognostic marker for CD19/CD3-bispecific T cell-engaging antibodies (blinatumomab) treatment against relapsed or refractory B-precursor acute lymphoblastic	23
SIGLEC10+ macrophages drive gastric cancer progression by suppressing CD8+ T cell function	23
Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases	22
Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors	22
Tumor-associated neutrophils upregulate PANoptosis to foster an immunosuppressive microenvironment of non-small cell lung cancer	22
Immune characteristics and prognostic implications of mucosal-associated invariant T cells in acute myeloid leukemia	22
STAT3 promotes differentiation of monocytes to MDSCs via CD39/CD73-adenosine signal pathway in oral squamous cell carcinoma	22
Murine regulatory T cells utilize granzyme B to promote tumor metastasis	21
Interaction of glioma-associated microglia/macrophages and anti-PD1 immunotherapy	21
Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection	20

A Listeria-based vaccine targeting ISG15 exerts anti-tumor efficacy in renal cell carcinoma	20
HPV-associated head and neck cancer is characterized by distinct profiles of CD8+ T cells and myeloid-derived suppressor cells	20
Blockade of tumor-derived colony-stimulating factor 1 (CSF1) promotes an immune-permissive tumor microenvironment	20
The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer	20
CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?	19
Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers	19
Correction to: TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism	19
Tumor immunology meets oncology (TIMO) XVII, April 20–22 2023 in Halle/Saale, Germany	19
Human colorectal cancer: upregulation of the adaptor protein Rai in TILs leads to cell dysfunction by sustaining GSK-3 activation and PD-1 expression	19
Brachyury-targeted immunotherapy combined with gemcitabine against head and neck cancer	19
Anti-PD-1 antibody-activated Th17 cells subvert re-invigoration of antitumor cytotoxic T-lymphocytes via myeloid cell-derived COX-2/PGE2	19
Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden	18
Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines	18
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study	18
Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding W	18
Combination of magnetic hyperthermia and immunomodulators to drive complete tumor regression of poorly immunogenic melanoma	18
Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis	18
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentri	18
Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia	18